Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208702 · ClinicalTrials.gov registry record · Phase 4
Thyroid Medication and Antidepressants for Treating Major Depression
A Phase 4 study of Major Depression, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 153
- Enrollment target
- 1
- Study location
NCT00208702: Completed Phase 4 study of Major Depression, sponsored by Emory University.
NCT00208702 is a Phase 4 study of Major Depression that has completed, run by Emory University. The registered enrollment target is 153 participants, below the 322-participant average among 28 other Major Depression trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00208702, a Phase 4 study of Major Depression, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 153 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effectiveness of treatment with supplemental triiodothyronine (T3, Cytomel) and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), in improving symptoms of major depressive disorder (MDD).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Sertraline
- DRUG Triiodothyronine
Study Locations (1)
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 1996-09 |
| Est. Completion | 2003-07 |
| Phase | Phase 4 |
What the finished NCT00208702 record still lists
NCT00208702 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, below the 322-participant average among 28 other Major Depression trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Major Depression appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00208702 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT00208702 about?
NCT00208702 is a clinical study titled "Thyroid Medication and Antidepressants for Treating Major Depression". This study will evaluate the effectiveness of treatment with supplemental triiodothyronine (T3, Cytomel) and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), in improving symptoms of major depressive disorder (MDD).
What is the current status of trial NCT00208702?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 153 participants. The study started on 1996-09. Estimated completion is 2003-07.
What conditions does trial NCT00208702 study?
This clinical trial studies the following conditions: Major Depression.
What interventions are being tested in trial NCT00208702?
The interventions under investigation include: Placebo (OTHER), Sertraline (DRUG), Triiodothyronine (DRUG).
Who is sponsoring clinical trial NCT00208702?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00208702 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00208702's enrollment target sits among peer trials
153 13th of 28 higher than 16 of 28 other Major Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.
COMPLETED · Phase 4
-
Preventing Depression Recurrence in Diabetes
COMPLETED · Phase 4
-
Pharmacotherapy in Depression With Panic Spectrum
COMPLETED · Phase 4
-
Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram
COMPLETED · Phase 4
-
Prozac Treatment of Major Depression: Discontinuation Study
COMPLETED · Phase 4
-
The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia